Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Agency: National Institutes of Health
Assistance Listings: 93.242 -- Mental Health Research Grants
Description
Eligibility
Eligible applicants
Education
- Independent school districts
- Private institutions of higher education
- Public and state institutions of higher education
Government
- Public and Indian housing authorities
- Federally recognized Native American tribal governments
- County governments
- Special district governments
- City or township governments
- State governments
Miscellaneous
- Other
Nonprofit
- Nonprofits non-higher education without 501(c)(3)
- Other Native American tribal organizations
- Nonprofits non-higher education with 501(c)(3)
Business
- For-profit organizations other than small businesses
- Small businesses
Additional information
Grantor contact information
Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Documents
| File name | Description | Last updated |
|---|---|---|
| PAR-25-226-Full-Announcement.html | PAR-25-226 Full Announcement Text | Nov 22, 2024 07:12 PM UTC |
Link to additional information
https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html
Closing: November 19, 2026
Award
$--
Program Funding
--
Expected awards
$--
Award Minimum
$--
Award Maximum
Funding opportunity number:
PAR-25-226
Cost sharing or matching requirement:
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
Category of Funding Activity:
Health
Category Explanation:
History
Version:
1
Posted date:
November 22, 2024
Archive date:
December 25, 2026
